twitter facebook instagram

Ljubljana

 

Slovenia , EU

Activity: education, training, counseling, monitoring, publishing, informing, raising awareness, proposing expert opinions or standpoints, offering expert advice and similar
Date: 28/08/2020
Time: 06:00 am
Location: Print Media , Radio, Television ( education, training, counseling, monitoring, publishing, informing, raising awareness, proposing expert opinions or standpoints, offering expert advice and similar )
Public/Private: Private
Individual/Organisation: Organisation
Name of Organisation: ICANNA- International Research Institute for Cannabinoids
Contact: Dusan Nolimal
Phone: 00 386 31 605 529
Email: Dusan.Nolimal@institute-icanna.com

ICANNA Institute achieves its goals through the implementation of research, development, analysis, education, training, counseling, monitoring, publishing, informing, raising awareness, proposing expert opinions or standpoints, offering expert advice and similar. Too many people have died from drug overdoses during last years. We will publish several articles to raise more awareness on gaps to be bridged in implementing of national drug strategy. The articles show significant gaps between the abitious strategic goals and policy actions adopted by the government and the reality perceived by different NGOs and our institute. The following is the summary of the articles and the ICANNA’s data and standpoint: Innovation harm reduction interventions such as naloxone distribution programs and drug consumption rooms are not available in Slovenia. Also, “good Good Samaritan law” is not available and there is no legal protection to people who give reasonable assistance to those who need drug related help. The poorly designed drug policy the state has also fueled overdose crises. For example, by focusing repressive drug policies on low level offenders and people who use drugs the state has also aggravated harms to public health. EU and the national governments must acknowledge the negative consequences of the repressive law enforcement approaches to drug policies and there should be more support for overdose prevention efforts by EU and national governments. The proposed New EU Drugs Agenda 2021-2025 and related EU Action Plan on Drugs continues to ignore some evidence: The most effective means to prevent deaths by overdose are still lacking across the EU.